🚀 VC round data is live in beta, check it out!
ADC Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for ADC Therapeutics and similar public comparables like Contineum Therapeutics, AIM Vaccine, Lexeo Therapeutics, TaiMed Biologics and more.
ADC Therapeutics Overview
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Founded
2011
HQ
Employees
265
Website
Sectors
Financials (LTM)
EV
$333M
ADC Therapeutics Financials
ADC Therapeutics reported last 12-month revenue of $81M.
In the same LTM period, ADC Therapeutics generated $75M in gross profit and had net loss of ($139M).
Revenue (LTM)
ADC Therapeutics P&L
In the most recent fiscal year, ADC Therapeutics reported revenue of $81M and EBITDA of ($88M).
ADC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $81M | XXX | $81M | XXX | XXX | XXX |
| Gross Profit | $75M | XXX | $76M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 93% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($88M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (108%) | XXX | XXX | XXX |
| EBIT Margin | (137%) | XXX | (132%) | XXX | XXX | XXX |
| Net Profit | ($139M) | XXX | ($143M) | XXX | XXX | XXX |
| Net Margin | (171%) | XXX | (175%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ADC Therapeutics Stock Performance
ADC Therapeutics has current market cap of $478M, and enterprise value of $333M.
Market Cap Evolution
ADC Therapeutics' stock price is $3.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $333M | $478M | 0.8% | XXX | XXX | XXX | $-1.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialADC Therapeutics Valuation Multiples
ADC Therapeutics trades at 4.1x EV/Revenue multiple, and (3.8x) EV/EBITDA.
EV / Revenue (LTM)
ADC Therapeutics Financial Valuation Multiples
As of April 11, 2026, ADC Therapeutics has market cap of $478M and EV of $333M.
Equity research analysts estimate ADC Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ADC Therapeutics has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $478M | XXX | $478M | XXX | XXX | XXX |
| EV (current) | $333M | XXX | $333M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.8x) | XXX | XXX | XXX |
| EV/EBIT | (3.0x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | 4.4x | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (3.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ADC Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ADC Therapeutics Margins & Growth Rates
ADC Therapeutics' revenue in the last 12 month grew by 17%.
ADC Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
ADC Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | (2%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (108%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (14%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 57% | XXX | 53% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 52% | XXX | 74% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 118% | XXX | 128% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 225% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ADC Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Contineum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| AIM Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| Lexeo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiMed Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Assembly Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ADC Therapeutics M&A Activity
ADC Therapeutics acquired XXX companies to date.
Last acquisition by ADC Therapeutics was on XXXXXXXX, XXXXX. ADC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ADC Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialADC Therapeutics Investment Activity
ADC Therapeutics invested in XXX companies to date.
ADC Therapeutics made its latest investment on XXXXXXXX, XXXXX. ADC Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ADC Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ADC Therapeutics
| When was ADC Therapeutics founded? | ADC Therapeutics was founded in 2011. |
| Where is ADC Therapeutics headquartered? | ADC Therapeutics is headquartered in United States. |
| How many employees does ADC Therapeutics have? | As of today, ADC Therapeutics has over 265 employees. |
| Who is the CEO of ADC Therapeutics? | ADC Therapeutics' CEO is Ameet Mallik. |
| Is ADC Therapeutics publicly listed? | Yes, ADC Therapeutics is a public company listed on NYSE. |
| What is the stock symbol of ADC Therapeutics? | ADC Therapeutics trades under ADCT ticker. |
| When did ADC Therapeutics go public? | ADC Therapeutics went public in 2020. |
| Who are competitors of ADC Therapeutics? | ADC Therapeutics main competitors are Contineum Therapeutics, AIM Vaccine, Lexeo Therapeutics, TaiMed Biologics. |
| What is the current market cap of ADC Therapeutics? | ADC Therapeutics' current market cap is $478M. |
| What is the current revenue of ADC Therapeutics? | ADC Therapeutics' last 12 months revenue is $81M. |
| What is the current revenue growth of ADC Therapeutics? | ADC Therapeutics revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of ADC Therapeutics? | Current revenue multiple of ADC Therapeutics is 4.1x. |
| Is ADC Therapeutics profitable? | No, ADC Therapeutics is not profitable. |
| What is the current net income of ADC Therapeutics? | ADC Therapeutics' last 12 months net income is ($139M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.